2022
Association of vancomycin plus piperacillin–tazobactam with early changes in creatinine versus cystatin C in critically ill adults: a prospective cohort study
Miano TA, Hennessy S, Yang W, Dunn TG, Weisman AR, Oniyide O, Agyekum RS, Turner AP, Ittner CAG, Anderson BJ, Wilson FP, Townsend R, Reilly JP, Giannini HM, Cosgriff CV, Jones TK, Meyer NJ, Shashaty MGS. Association of vancomycin plus piperacillin–tazobactam with early changes in creatinine versus cystatin C in critically ill adults: a prospective cohort study. Intensive Care Medicine 2022, 48: 1144-1155. PMID: 35833959, PMCID: PMC9463324, DOI: 10.1007/s00134-022-06811-0.Peer-Reviewed Original ResearchConceptsPiperacillin-tazobactamKidney biomarkersCystatin CAcute kidney injury riskProspective cohort studyCystatin C concentrationCystatin C measurementKidney function biomarkersCreatinine secretionAntibiotic initiationCohort studyProspective cohortIll adultsClinical outcomesAssociation of vancomycinAntibiotic treatmentTubular secretionCreatinine concentrationTreatment weightingResultsThe studyTrue injuryHigh incidenceCreatinineDay 14Early changesAngiopoietins as Prognostic Markers for Future Kidney Disease and Heart Failure Events after Acute Kidney Injury
Mansour SG, Bhatraju PK, Coca SG, Obeid W, Wilson FP, Stanaway IB, Jia Y, Thiessen-Philbrook H, Go AS, Ikizler TA, Siew ED, Chinchilli VM, Hsu CY, Garg AX, Reeves WB, Liu KD, Kimmel PL, Kaufman JS, Wurfel MM, Himmelfarb J, Parikh SM, Parikh CR. Angiopoietins as Prognostic Markers for Future Kidney Disease and Heart Failure Events after Acute Kidney Injury. Journal Of The American Society Of Nephrology 2022, 33: 613-627. PMID: 35017169, PMCID: PMC8975075, DOI: 10.1681/asn.2021060757.Peer-Reviewed Original ResearchConceptsCKD progressionHeart failureLower riskAngpt-1Highest quartileFuture kidney diseaseSetting of AKIAcute kidney injuryHeart failure admissionsHeart failure eventsProspective cohort studyMortality 3 monthsPlasma angiopoietinsKidney injuryCohort studySecondary outcomesEndothelial injuryMedian agePrimary outcomeKidney diseasePrognostic markerAngiopoietin-2AKIAngiopoietin-1Vessel destabilization
2021
Rationale and design of the Kidney Precision Medicine Project
de Boer IH, Alpers CE, Azeloglu EU, Balis UGJ, Barasch JM, Barisoni L, Blank KN, Bomback AS, Brown K, Dagher PC, Dighe AL, Eadon MT, El-Achkar TM, Gaut JP, Hacohen N, He Y, Hodgin JB, Jain S, Kellum JA, Kiryluk K, Knight R, Laszik ZG, Lienczewski C, Mariani LH, McClelland RL, Menez S, Moledina DG, Mooney SD, O’Toole J, Palevsky PM, Parikh CR, Poggio ED, Rosas SE, Rosengart MR, Sarwal MM, Schaub JA, Sedor JR, Sharma K, Steck B, Toto RD, Troyanskaya OG, Tuttle KR, Vazquez MA, Waikar SS, Williams K, Wilson FP, Zhang K, Iyengar R, Kretzler M, Himmelfarb J, Project K, Knight R, Lecker S, Stillman I, Waikar S, Mcmahon G, Weins A, Short S, Hacohen N, Hoover P, Aulisio M, Cooperman L, Herlitz L, O’Toole J, Poggio E, Sedor J, Jolly S, Appelbaum P, Balderes O, Barasch J, Bomback A, Canetta P, d’Agati V, Kiryluk K, Kudose S, Mehl K, Radhakrishnan J, Weng C, Barisoni L, Alexandrov T, Ashkar T, Barwinska D, Dagher P, Dunn K, Eadon M, Ferkowicz M, Kelly K, Sutton T, Winfree S, Menez S, Parikh C, Rosenberg A, Villalobos P, Malik R, Fine D, Atta M, Trujillo J, Slack A, Rosas S, Williams M, Azeloglu E, He C, Iyengar R, Hansen J, Parikh S, Rovin B, Anderton C, Pasa-Tolic L, Velickovic D, Lukowski J, Oliver G, Ardayfio J, Bebiak J, Brown K, Campbell T, Campbell C, Hayashi L, Jefferson N, Koewler R, Roberts G, Saul J, Shpigel A, Stutzke E, Wright L, Miegs L, Pinkeney R, Sealfon R, Troyanskaya O, Tuttle K, Dobi D, Goltsev Y, Lake B, Zhang K, Joanes M, Laszik Z, Schroeder A, Sarwal M, Sigdel T, Balis U, Blanc V, He O, Hodgin J, Kretzler M, Mariani L, Menon R, Otto E, Schaub J, Steck B, Lienczewski C, Eddy S, Elder M, Hall D, Kellum J, Kruth M, Murugan R, Palevsky P, Randhawa P, Rosengart M, Sims-Lucas S, Stefanick M, Stull S, Tublin M, Alpers C, de Boer I, Dighe A, Himmelfarb J, Mcclelland R, Mooney S, Shankland S, Williams K, Blank K, Carson J, Dowd F, Drager Z, Park C, Sharma K, Zhang G, Bansal S, Venkatachalam M, Kermani A, Lee S, Lu C, Miller T, Moe O, Park H, Sambandam K, Sanchez F, Torrealba J, Robert T, Vazquez M, Wang N, Gaut J, Jain S, Vijayan A, Luciano R, Moledina D, Ugochukwu U, Wilson F, Alfano S. Rationale and design of the Kidney Precision Medicine Project. Kidney International 2021, 99: 498-510. PMID: 33637194, PMCID: PMC8330551, DOI: 10.1016/j.kint.2020.08.039.Peer-Reviewed Original ResearchConceptsAcute kidney injuryChronic kidney diseaseKidney Precision Medicine ProjectKidney biopsyKidney diseasePrecision Medicine ProjectKidney tissueMulticenter prospective cohort studyProtocol kidney biopsiesProspective cohort studyDeep clinical phenotypingPrecision medicine approachMedicine ProjectKidney injuryClinical characteristicsCohort studyClinical outcomesSubgroup analysisMorbid diseaseNovel therapiesPreventive strategiesClinical phenotypingDisease subgroupsToxic injuryPatients
2020
Novel Risk Factors for Progression of Diabetic and Nondiabetic CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study
Anderson AH, Xie D, Wang X, Baudier RL, Orlandi P, Appel LJ, Dember LM, He J, Kusek JW, Lash JP, Navaneethan SD, Ojo A, Rahman M, Roy J, Scialla JJ, Sondheimer JH, Steigerwalt SP, Wilson FP, Wolf M, Feldman HI, Investigators C, Go A, Townsend R. Novel Risk Factors for Progression of Diabetic and Nondiabetic CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study. American Journal Of Kidney Diseases 2020, 77: 56-73.e1. PMID: 32866540, PMCID: PMC7752839, DOI: 10.1053/j.ajkd.2020.07.011.Peer-Reviewed Original ResearchConceptsChronic Renal Insufficiency Cohort (CRIC) StudyIndependent risk factorCKD progressionNovel risk factorsRisk factorsCohort studyComposite outcomeN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideChronic kidney disease progressionGlomerular filtration rate (eGFR) slopeHigh-sensitivity troponin TCox proportional hazards modelStudy designProgression of diabeticsUrinary neutrophil gelatinaseUrinary NGAL levelsUS clinical centersKidney disease progressionLow serum bicarbonateProspective cohort studyKidney replacement therapyHigh-risk subgroupsProportional hazards modelNumerous risk factors
2018
Biomarkers of AKI Progression after Pediatric Cardiac Surgery
Greenberg JH, Zappitelli M, Jia Y, Thiessen-Philbrook HR, de Fontnouvelle CA, Wilson FP, Coca S, Devarajan P, Parikh CR. Biomarkers of AKI Progression after Pediatric Cardiac Surgery. Journal Of The American Society Of Nephrology 2018, 29: 1549-1556. PMID: 29472416, PMCID: PMC5967766, DOI: 10.1681/asn.2017090989.Peer-Reviewed Original ResearchConceptsAKI progressionOptimism-corrected areaIL-8First dayStage 3 AKIUrine L-FABPProspective cohort studyBiomarkers of inflammationPediatric cardiac surgeryConfidence intervalsAKI stagePostoperative AKIKidney injuryCohort studySerum creatinineCardiac surgeryCardiopulmonary bypassTherapeutic trialsUrine biomarkersAdverse outcomesHospitalized childrenPlasma biomarkersClinical careAdditional cohortAKI